ARTICLE | Company News

Merck KGaA, Pfizer, Accelerated Cure Project autoimmune news

September 15, 2014 7:00 AM UTC

Merck's EMD Serono Inc. biopharmaceutical division is providing at least $1 million in funding to the non-profit for a longitudinal U.S. study focused on obtaining real-world data from multiple sclerosis patients. The Optimizing Treatment -- Understanding Progression (OPT-UP) study, slated to start in 1Q15, will enroll 2,500 MS patients and follow them for up to five years to collect data to help optimize treatment and understand progression. ...